Aclarion 将来の成長

Future 基準チェック /26

Aclarionの収益は年間6.4%で減少すると予測されていますが、年間収益は年間136.3%で増加すると予想されています。EPS は年間46.7%で増加すると予想されています。

主要情報

-6.4%

収益成長率

46.7%

EPS成長率

Healthcare Services 収益成長	30.8%
収益成長率	136.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	24 Aug 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

NasdaqCM:ACON - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	-7	N/A	-6	2
12/31/2024	-7	N/A	-7	2
9/30/2024	-6	-5	-5	N/A
6/30/2024	-6	-5	-5	N/A
3/31/2024	-6	-5	-5	N/A
12/31/2023	-5	-4	-4	N/A
9/30/2023	-5	-4	-4	N/A
6/30/2023	-5	-4	-4	N/A
3/31/2023	-7	-6	-6	N/A
12/31/2022	-7	-5	-5	N/A
9/30/2022	-8	-5	-5	N/A
6/30/2022	-9	-5	-4	N/A
3/31/2022	-6	-3	-2	N/A
12/31/2021	-6	-3	-2	N/A
9/30/2021	-5	-2	-2	N/A
6/30/2021	-5	-4	-3	N/A
3/31/2021	-5	-4	-3	N/A
12/31/2020	-5	-4	-4	N/A
12/31/2019	-5	-4	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ACON今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ACON今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ACON今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ACONの収益 ( 136.3% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: ACONの収益 ( 136.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ACONの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Aclarion 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Aclarion Provides Update on Non-Compliance with Nasdaq’s Stockholders’ Equity Requirement and Nasdaq’s Bid Price Requirement

Aclarion, Inc. announced that it has received $1 million in funding

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Aclarion, Inc. has filed a Follow-on Equity Offering in the amount of $1.075 million.

Aclarion Launches Surgeon Partnership to Apply Nociscan's Ai Technology to Personal Injury and Workers Compensation Market

Aclarion Receives Non-Compliance Letter from Nasdaq Due to Non-Compliance with the Nasdaq Minimum Stockholders’ Equity Requirement

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.44 loss per share (vs US$2.39 loss in 1Q 2023)

Aclarion Receives Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Aclarion, Inc. has completed a Composite Units Offering in the amount of $3.0015 million.

Full year 2023 earnings released: US$8.82 loss per share (vs US$19.61 loss in FY 2022)

Aclarion Announces Updated Product Release That Expands Mri Scanner Access for Nociscan Solution

New major risk - Shareholder dilution

Aclarion, Inc. announced that it has received $0.25 million in funding

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.21 loss in 3Q 2022)

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Nasdaq Staff Determines to Delist the Aclarion Common Stock from Nasdaq, Unless the Company Timely Requests an Appeal of the Staff’s Determination to A Hearings Panel

Nasdaq Confirms Aclarion Regains Compliance with Rule 5250(c)(1) Regarding Filing of 10-Q Report

Aclarion Announces Update on Non-Compliance Notice from Nasdaq Regarding Late Filing of 10-Q Report

High number of new and inexperienced directors

Aclarion Receives Non-Compliance Notice From Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aclarion, Inc. Receives Nasdaq Notice Regarding Late Filing of 10-Q Report

Aclarion, Inc. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.25 loss per share (vs US$6.58 loss in FY 2021)

Aclarion, Inc. George Frey MD as Key Opinion Leader

Aclarion, Inc. Receives a Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Aclarion, Inc’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

High number of new directors

Aclarion, Inc.'s Nociscan Selected for Inclusion in Pivotal National Institutes of Health Study for Low Back Pain

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

First quarter 2022 earnings released: US$1.35 loss per share (vs US$0.81 loss in 1Q 2021)

Director recently bought US$150k worth of stock

High number of new directors

Aclarion, Inc. has completed an IPO in the amount of $9.41775 million.

Aclarion, Inc. has completed an IPO in the amount of $9.41775 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘